Literature DB >> 17420930

Pharmacodynamics of interferon beta in multiple sclerosis patients with or without serum neutralizing antibodies.

Carolina Scagnolari1, Petra Duda, Francesca Bagnato, Gabriella De Vito, Alessia Alberelli, Vito Lavolpe, Enrico Girardi, Valentina Durastanti, Maria Trojano, Ludwig Kappos, Guido Antonelli.   

Abstract

To analyze the in vivo biological effect of anti-interferon beta (IFN-beta) neutralizing antibodies (NABs), blood concentrations of neopterin, beta2microglobulin (Beta2-MG), mRNA-dependent myxovirusresistant protein A (MxA) and dsRNA-dependent protein kinase (PKR) were measured before (predose) and 24 hours after (postdose) IFN-beta administration in 49 patients with multiple sclerosis (MS) with (n = 25) and without (n = 24) NABs. The results indicated that predose levels of MxA-mRNA and PKR-mRNA were highly variable [coefficient of variation (CV) > 100%] among patients. A lower inter-individual variability was observed for pre-dose levels of Beta2-MG and neopterin (CVs of 29% and 44%, respectively). Significantly lower pre- and post-dose blood levels of IFN induced markers, except for postdose PKR-mRNA (p = 0.09), were seen in NAB+ compared with NAB-patients and between patients with high (> 200 t(1/10)) and low ( pound 200 t(1/10)) NAB titers. A significant inverse correlation between NAB titer and pre-dose levels of the above IFN-induced markers was found. In summary, our findings confirm that NABs affect absolute concentrations of IFN-beta induced markers and suggest that such an effect occurs in a titer-dependent manner.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17420930     DOI: 10.1007/s00415-006-0332-7

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  50 in total

1.  The neutralization of interferons by antibody. I. Quantitative and theoretical analyses of the neutralization reaction in different bioassay systems.

Authors:  S E Grossberg; Y Kawade; M Kohase; H Yokoyama; N Finter
Journal:  J Interferon Cytokine Res       Date:  2001-09       Impact factor: 2.607

2.  Quantitation of neutralization of interferon by antibody.

Authors:  Y Kawade
Journal:  Methods Enzymol       Date:  1986       Impact factor: 1.600

3.  Randomized controlled trial of interferon-beta-1a in secondary progressive MS: MRI results.

Authors:  D K Li; G J Zhao; D W Paty
Journal:  Neurology       Date:  2001-06-12       Impact factor: 9.910

4.  Identification of a single nucleotide polymorphism in the MxA gene promoter (G/T at nt -88) correlated with the response of hepatitis C patients to interferon.

Authors:  M Hijikata; Y Ohta; S Mishiro
Journal:  Intervirology       Date:  2000       Impact factor: 1.763

5.  A one-year study on the pharmacodynamic profile of interferon-beta1a in MS.

Authors:  F Bagnato; C Pozzilli; C Scagnolari; F Bellomi; P Pasqualetti; C Gasperini; E Millefiorini; S Galgani; M Spadaro; G Antonelli
Journal:  Neurology       Date:  2002-05-14       Impact factor: 9.910

6.  Interferon-beta (INF-beta) antibodies in interferon-beta1a- and interferon-beta1b-treated multiple sclerosis patients. Prevalence, kinetics, cross-reactivity, and factors enhancing interferon-beta immunogenicity in vivo.

Authors:  P Perini; A Facchinetti; P Bulian; A R Massaro; D D Pascalis; A Bertolotto; G Biasi; P Gallo
Journal:  Eur Cytokine Netw       Date:  2001-03       Impact factor: 2.737

Review 7.  Development of interferon-beta as a therapy for multiple sclerosis.

Authors:  Clyde Markowitz
Journal:  Expert Opin Emerg Drugs       Date:  2004-11       Impact factor: 4.191

8.  Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group.

Authors: 
Journal:  Lancet       Date:  1998-11-07       Impact factor: 79.321

9.  No evidence for genetic linkage between development of multiple sclerosis and components of the IFN system and the JAK-STAT pathway.

Authors:  M Bergkvist; M Olsson; M Sandberg-Wollheim
Journal:  Mult Scler       Date:  2004-02       Impact factor: 6.312

10.  Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

Authors:  L D Jacobs; D L Cookfair; R A Rudick; R M Herndon; J R Richert; A M Salazar; J S Fischer; D E Goodkin; C V Granger; J H Simon; J J Alam; D M Bartoszak; D N Bourdette; J Braiman; C M Brownscheidle; M E Coats; S L Cohan; D S Dougherty; R P Kinkel; M K Mass; F E Munschauer; R L Priore; P M Pullicino; B J Scherokman; R H Whitham
Journal:  Ann Neurol       Date:  1996-03       Impact factor: 10.422

View more
  6 in total

1.  Neutralizing antibodies against interferon-Beta.

Authors:  Per Soelberg Sorensen
Journal:  Ther Adv Neurol Disord       Date:  2008-09       Impact factor: 6.570

Review 2.  Determinants of interferon β efficacy in patients with multiple sclerosis.

Authors:  Joep Killestein; Chris H Polman
Journal:  Nat Rev Neurol       Date:  2011-03-01       Impact factor: 42.937

Review 3.  Neutralizing antibodies to interferon-beta and other immunological treatments for multiple sclerosis: prevalence and impact on outcomes.

Authors:  Florian Deisenhammer
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

4.  Use of a standardized MxA protein measurement-based assay for validation of assays for the assessment of neutralizing antibodies against interferon-β.

Authors:  Meenu Wadhwa; Meena Subramanyam; Susan Goelz; Jaya Goyal; Vijay Jethwa; Wendy Jones; James G Files; Daniel Kramer; Chris Bird; Paula Dilger; Michael Tovey; Christophe Lallemand; Robin Thorpe
Journal:  J Interferon Cytokine Res       Date:  2013-07-13       Impact factor: 2.607

5.  Neopterin production and tryptophan degradation during 24-months therapy with interferon beta-1a in multiple sclerosis patients.

Authors:  Valentina Durastanti; Alessandra Lugaresi; Placido Bramanti; Mariapia Amato; Paolo Bellantonio; Giovanna De Luca; Orietta Picconi; Roberta Fantozzi; Laura Locatelli; Annalisa Solda'; Edoardo Sessa; Rocco Totaro; Silvia Marino; Valentina Zipoli; Marino Zorzon; Enrico Millefiorini
Journal:  J Transl Med       Date:  2011-04-18       Impact factor: 5.531

6.  Neutralizing antibodies explain the poor clinical response to interferon beta in a small proportion of patients with multiple sclerosis: a retrospective study.

Authors:  Emilia Sbardella; Valentina Tomassini; Claudio Gasperini; Francesca Bellomi; Luca Ausili Cefaro; Vincenzo Brescia Morra; Guido Antonelli; Carlo Pozzilli
Journal:  BMC Neurol       Date:  2009-10-13       Impact factor: 2.474

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.